Red Laboratories at the Crypto-Infections Dublin Ireland Sept. 26-27, 2020; Bron http://blog.redlaboratories.be/2020/01/ ... tions.html..phage test results will be presented but the event is for medical professionals only..
Agenda; Bron https://www.lymeresourcecentre.com/syst ... v%2025.pdf
2-Neglected Infections And Gastrointestinal Issues In Patients With Late/Persistent/Chronic Vector-Borne Infections - Tanja Mijatovic
3-Specific Borrelia phages as new strategies for diagnostics - Louis Teulieres
Interessant is of er nieuwe ontwikkelingen zijn op het gebied van bijvoorbeeld de testen voor Bartonella en de andere co-infecties en de stand van zaken van de validatie en verificatie onderzoeksresultaten!
Lymevereniging 2020; Bron https://nl-nl.facebook.com/lymevereniging/
Niet in de uitzending: aan de Universiteit van Leicester is een onderzoeksgroep die, mede met subsidie van het Lymefonds, werkt aan een test om met bacteriofagen een actieve lyme-infectie vast te stellen. Zij werken ook aan een bartonellatest. Daarna gaan ze werken aan bacteriofagen inzetten om lyme te behandelen, maar dat bleek lastiger dan men aanvankelijk dacht.
En of er nieuwe ontwikkelingen zijn op het gebied van de lopende patent(octrooi) procedure bij European Patent Office (EPO) Den Haag.
'Bacteriophage Lyme Test Offers ME/CFS Patient New Possibility'; Bron https://www.healthrising.org/blog/2020/ ... eriophage/
Het patent(octrooi) is (nog) niet verleend!I have also contacted the Chief Science Officer at RED and Phelix requesting scientific evidence backing up the Phage Test.
I have been told that as it is ongoing a patent application, they cannot publish scientific articles at the same time. They will do so when the patent is granted.
European Patent Office (EPO): 'Phage-Based detection of Borreliosis and means therefor' patentnr. WO2018083491A1 (detection method) - EP3535412; Bron https://www.epo.org/
De patent(octrooi) aanvraag is in behandeling. Abstract WO2018083491A1 - EP3535412; Bron https://register.epo.org/application?nu ... ab=doclist Het patent(octrooi) kan worden verleend of worden afgewezen.
Stand van zaken: Communication from the Examining Division 30 juni 2020
Artikel 94(3): 'De aanvraag voldoet niet aan de voorwaarden van het EPO. Indien de tekortkomingen niet worden gerectificeerd kan de toepassing worden geweigerd'. 'Voor de observaties en de correcties geldt een termijn van 4 maanden'.
2020 ILADS Annual Scientific Virtual Conference
ONE HEALTH LYME – The intersection of Lyme and COVID; Bron https://www.ilads.org/ilads-conference/ ... ence-2020/
Spreker Tatjana Mijatovic van Red Laboratories
Lyme Disease – Are We Looking for a Wrong Culprit?
Tatjana Mijatovic, PhD
Background: Borrelia-related diseases (Lyme disease and relapsing fevers) are increasingly prevalent, severe, difficult to diagnose and treat. The high failure rate of tick-borne infection testing undermine treatments‘ strategy and monitoring.
Aims: The goal of this contribution is to bring the focus on the importance to enlarge borreliosis-related testing targets and shed some light on high prevalence of B. miyamotoi presence both in ticks and late stage undiagnosed patients.
Methods: Bacteriophages could become a diagnostic tool based on the principle that if there are phages it is because there are living bacteria. Phelix Charity together with Leicester University microbiology department have recently developed a Borrelia Phage-based PCR test searching for 3 major Borrelia groups (Borrelia burgdorferi sl (including B. burgdorferi ss, B. afzelii, B. garinii, B. spielmanii, etc), Borrelia miyamotoi and Relapsing fever group (B. recurrentis, B. hermsii, etc). This method is efficiently used to assess both human samples and ticks.
Results: Since July 2019, over 2100 results from patients originating various countries have been obtained. Testing included mainly late stage/chronic patients and the aggregated data are showing 30% negative results and 70% positive among which over 60% indicated the presence of specific Borrelia miyamotoi phages. Furthermore, ticks from 2019 and 2020 have been analyzed by the same method. The obtained results on ticks showed that over 60% were found positive for Borrelia miyamotoi and only 15% for B. burgdorferi sl.
Conclusion: This is the first large scale report on prevalence of B. miyamotoi in the ticks, as well as in late stages of borreliosis. Seen a high prevalence of B. miyamotoi in tested ticks, further supported by similar percentages found in tested patients, one can hypothesize that the high failure rate of current two-tier screening testing, searching for B. burgdorferi sl only, might be due to the wrong testing target. In other words, the overall high expansion of undiagnosed Lyme disease cases worldwide might be linked to the screening choice focusing only on B. burgdorferi sl and only rarely testing for B. miyamotoi while the later one seems to be much more prevalent. Further accumulation of data both from the patients and ticks should bring the answer to the question are we searching for a wrong culprit. Searching for actual bacterial presence using phage-based testing might pacify the debate and controversies on testing choices and late/chronic stage patients.
Het zijn nogal opmerkelijke uitspraken 'Zijn we op zoek naar een verkeerde boosdoener?'.. dat de halve wereld met name in Europa, de Lyme en de chronische Lyme patiënten, B. miyamotoi hebben en geen Borrelia burgdorferi? Uitspraken gedaan op basis van een niet-gevalideerde test, in een lopend (wetenschappelijk) onderzoek?
'Newsletter Phelix december 2019'; Bron https://iforlyme.org/downloads/phelix-p ... 201912.pdf
Er zijn bloed, speeksel, urine stalen verzameld van 2.000 mensen uit België, Frankrijk, VK, Rusland, Duitsland, Nederland, Verenigde Staten en uit Canada). Is er onderscheid gemaakt tussen de Europese en Amerikaanse varianten? Hoeveel teken en uit welke landen zijn er getest?
Op basis van enkel de Phelix Phage Borrelia test krijgen de Lyme- en de chronische Lyme patiënten en de me/cvs patiënten bij Ilads artsen dezelfde behandelingen met een zwaar antibiotica protocol in combinatie met disulfiram en dapsone. Tot nu toe worden er weinig tot geen ervaringen gedeeld waarbij patiënten een goede en of blijvende verbetering of herstel hebben gekregen.
Het is te hopen dat de wetenschappers en uitvinders Jinyu Shan & Martha Clockie en Louis Teulières met een goede wetenschappelijke onderbouwing gaan komen en het niet een volgend 'xmrv-mlv-virus debacle' gaat worden.
Spreker Louis Teulières van Phelix
Zijn de Covid-19 testen en de andere testen van Red Laboratories betrouwbare en gevalideerde testen? Het laboratorium heeft geen ISO 15189 certificaat van het BELAC België (de Belgische Accreditatie-instelling - Medische laboratoria (MED); Bron https://economie.fgov.be/nl/themas/kwal ... atoria-medSpecific PCR Phages Tests Show Borrelia miyamotoï More Realistic Prevalence in Europe. COVID/LD Co-Infection Markers and Shared Treatments
Louis Teulieres, MD, PhD
Specific PCR phages tests show Borrelia miyamotoï more realistic prevalence in Europe. Covid /LD co infection markers and shared treatments.
Introduction
Phages are specific viruses. Inserting their genetic material in their host, they can either produce numerous copies that further destroy the bacteria, or stay in a dormant lysogenic stage and be expressed under specific circumstances.
Phelix Charity and Leicester University developed a Borrelia SL and a specific B. miyamotoi Phage PCR tests already validated in early and late stage patients and healthy volunteers, showing >90% sensitivity and 100% specificity.
Goal
Phages being an evidence of bacterial activity, this technology is an in-vivo amplification system for active infections. Clinicians can evaluate their treatments and discriminate the active disease from the post-lyme syndrome. Borrelia phage based PCR experience is being used for Bartonella spp., Rickettsia spp tests’ developments, and testing new anti infectious compounds and strategies
Methods
Borrelia SL and a specific B. miyamotoi Phages PCR Tests were performed on 2200 samples (all late stage) from various European countries and from USA All results were verified by sequencin.
Results
30% of the 2200 samples were negative, 70% positive among which 60% Borrelia miyamotoi.
Interestingly, 20 positive patients were also early stage symptomatic COVID-19 cases (anosmia; cough and dyspnea; fever) Immunological and hematological evaluation put in evidence Th1/TH2 imbalance, D dimers increase, Low IL10, high expression of IL 1 andIL-6. Successful treatment was 7/8 days with macrolids (clarithromycin 500mg X2), atovaquone 200mg (or indomethacin: 3 x25 mg)/day.
Conclusions
This is the first large scale report on prevalence of B. miyamotoi in late stages of borreliosis in Europe. Results were permitted by the high sensitivity of Phages PCR tests. B miyamotoi resistance to antibiotics and predominant information exchange via plasmids may explain the greater prevalence of miyamotoï type persisters.
Tick biting season should provide genetic typing in early stages, (before antibody production) that will be presented. Early sequential treatment may be helpful to limit serious cases of COVID-19 incidence and tackle morbidities due to LD/COVID coinfections.